...
首页> 外文期刊>Allergy >IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1
【24h】

IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1

机译:舌下βv 1的舌下免疫疗法后的Ige-Cross-rescling抗体v 1

获取原文
获取原文并翻译 | 示例
           

摘要

Background Evidence has accumulated that birch pollen immunotherapy reduces rhinoconjunctivitis to pollen of birch homologous trees. Therapeutic efficacy has been associated with IgE-blocking IgG antibodies. We have recently shown that sera collected after 16 weeks of sublingual immunotherapy with recombinant Bet v 1 (rBet v 1-SLIT) display strong IgE-blocking bioactivity for Bet v 1. Here, we assessed whether rBet v 1-SLIT-induced IgG antibodies display cross-blocking activity to related allergens in Fagales pollen.
机译:None

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号